论文部分内容阅读
目的:探讨尿激酶对急性脑梗死(发病12小时内)静脉溶栓治疗的疗效与安全性比较。方法:将符合急性脑梗死(发病12小时内)入选标准的56例随机分为溶栓组29例和对照组27例。溶栓组接受尿激酶75万单位,其他治疗原则两组相同。采用欧洲卒中量表评价神经功能恢复情况。结果:溶栓组溶栓后3小时、1日、7日的欧洲卒中量表分值增加明显,21日时为(73±16),疗效显著优于对照组(64±15),P<0.05。颅内出血和其他系统出血率相近,溶栓组为10%,对照组为7%。21日时两组均无死亡病例。结论:尿激酶75万单位用于急性脑梗死(发病12小时内)静脉溶栓治疗有效,且相对比较安全。
Objective: To investigate the efficacy and safety of urokinase in the treatment of acute cerebral infarction (within 12 hours of onset) by intravenous thrombolysis. Methods: Fifty-six patients eligible for acute cerebral infarction (within 12 hours of onset) were randomly divided into thrombolytic group (n = 29) and control group (n = 27). Thrombolytic group to accept 750,000 units of urokinase, the other two principles of treatment the same. Assessment of neurological recovery using the European Stroke Scale. Results: The score of Stroke Scale increased significantly at 3 hours, 1 day and 7 days after thrombolysis in thrombolysis group, with a score of (73 ± 16) at 21 days, which was significantly better than that of control group (64 ± 15), P < 0.05. Intracranial hemorrhage and other bleeding rates were similar, thrombolysis group was 10%, control group was 7%. No deaths occurred in both groups on the 21st. Conclusion: 7.5 million units of urokinase are effective for intravenous thrombolysis in patients with acute cerebral infarction (within 12 hours of onset), and are relatively safe.